A Ten Trillion Dollar Industry Has Started Telling Its Customers to Stop Optimising

The awkward part is that the interventions with the best evidence are mostly free. A consistent schedule, a dark and cool room, light in the morning, less alcohol, and not doing anything about it at three in the morning. An industry cannot build a 10 trillion dollar category on that, which is why the products keep arriving, a tension we set out in the business of tracking, hacking and buying sleep.

And longevity?

This is where a reader should be most careful.

Up to 60 per cent of consumers across markets now say longevity is a top or very important priority, and the 2026 reports describe the focus shifting towards women's healthspan, including work on ovarian ageing rather than symptom management alone.

That specific shift is a genuine and overdue correction. Women's mid life health has been under researched for decades, and moving from managing symptoms to understanding the underlying biology is the right direction.

What does not follow is that the products sold under the longevity heading are supported by the same evidence. The gap between a legitimate research field and a retail category using its vocabulary is very wide, and it is where most of the money is being spent. The reasonable test is the same one that applies to any health claim: ask what outcome was measured, in how many people, over how long, and against what comparison.

Is the backlash real or is it marketing?

Both, and the fact that it is marketing does not make it wrong.

Trend reports are produced by organisations that serve the industry they describe, and a pivot to gentleness is also a new product line. Expect restorative to appear on a great deal of packaging.

But the underlying observation is supported by ordinary experience. Turning rest into a performance metric makes rest worse. People who track sleep obsessively often sleep less well, because the tracking introduces exactly the anxiety that prevents it. An industry acknowledging that, even for commercial reasons, is more useful than one that does not.

What is worth carrying away?

Three things.

The dimensions people care about outnumber the ones that can be measured. Any product that scores you is, by construction, working on a subset, and it will make that subset feel like the whole.

The interventions with the strongest evidence remain unglamorous and cheap. Sleep, movement, food, company. Nothing in the 2026 forecasts changes that ranking.

A backlash against optimisation is not a licence to ignore evidence. The failure mode of the last decade was measuring the wrong things obsessively. The failure mode of the next one will be treating evidence itself as part of the problem, which is a worse mistake, and one we have watched play out in which wellness trends actually stick.